Last reviewed · How we verify
ragweed pollen
Ragweed pollen allergen extract desensitizes the immune system to ragweed pollen through repeated controlled exposure, reducing allergic responses.
Ragweed pollen allergen extract desensitizes the immune system to ragweed pollen through repeated controlled exposure, reducing allergic responses. Used for Ragweed pollen-induced allergic rhinitis and asthma.
At a glance
| Generic name | ragweed pollen |
|---|---|
| Sponsor | The University of Texas Medical Branch, Galveston |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
This is an allergen immunotherapy product containing ragweed pollen extract that works by gradually exposing patients to increasing doses of the allergen. Over time, this exposure induces immune tolerance through shifts in T-cell responses and increased regulatory T cells, reducing IgE-mediated allergic reactions and symptoms upon natural exposure to ragweed pollen.
Approved indications
- Ragweed pollen-induced allergic rhinitis and asthma
Common side effects
- Local injection site reactions (itching, swelling, erythema)
- Oral pruritus and throat irritation
- Systemic allergic reactions
Key clinical trials
- Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis (NA)
- Vestibular Versus Sublingual Route of AIT Tablets (PHASE4)
- Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy (PHASE3)
- Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A) (PHASE1)
- Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test (PHASE2)
- Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber (PHASE1, PHASE2)
- Examining the Link Between Depression and Seasonal Allergies
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ragweed pollen CI brief — competitive landscape report
- ragweed pollen updates RSS · CI watch RSS
- The University of Texas Medical Branch, Galveston portfolio CI